TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. L. AU - Torre, L. A. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin. VL - 68 UR - https://doi.org/10.3322/caac.21492 DO - 10.3322/caac.21492 ID - Bray2018 ER - TY - JOUR AU - Varn, F. S. AU - Schaafsma, E. AU - Wang, Y. AU - Cheng, C. PY - 2018 DA - 2018// TI - Genomic characterization of six virus-associated cancers identifies changes in the tumor immune microenvironment and altered genetic programs JO - Cancer Res. VL - 78 ID - Varn2018 ER - TY - JOUR AU - Plummer, M. AU - Martel, C. AU - Vignat, J. AU - Ferlay, J. AU - Bray, F. AU - Franceschi, S. PY - 2016 DA - 2016// TI - Global burden of cancers attributable to infections in 2012: a synthetic analysis JO - Lancet Glob Health. VL - 4 UR - https://doi.org/10.1016/S2214-109X(16)30143-7 DO - 10.1016/S2214-109X(16)30143-7 ID - Plummer2016 ER - TY - JOUR AU - Mesri, E. A. AU - Feitelson, M. A. AU - Munger, K. PY - 2014 DA - 2014// TI - Human viral oncogenesis: a cancer hallmarks analysis JO - Cell Host Microbe. VL - 15 UR - https://doi.org/10.1016/j.chom.2014.02.011 DO - 10.1016/j.chom.2014.02.011 ID - Mesri2014 ER - TY - JOUR AU - Krump, N. A. AU - You, J. PY - 2018 DA - 2018// TI - Molecular mechanisms of viral oncogenesis in humans JO - Nat Rev Microbiol. VL - 16 UR - https://doi.org/10.1038/s41579-018-0064-6 DO - 10.1038/s41579-018-0064-6 ID - Krump2018 ER - TY - JOUR AU - Samra, B. AU - Tam, E. AU - Baseri, B. AU - Shapira, I. PY - 2018 DA - 2018// TI - Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives JO - J Investig Med. VL - 66 UR - https://doi.org/10.1136/jim-2018-000743 DO - 10.1136/jim-2018-000743 ID - Samra2018 ER - TY - JOUR AU - Felice, F. AU - Marchetti, C. AU - Palaia, I. AU - Ostuni, R. AU - Muzii, L. AU - Tombolini, V. PY - 2018 DA - 2018// TI - Immune check-point in cervical cancer JO - Crit Rev Oncol Hematol. VL - 129 UR - https://doi.org/10.1016/j.critrevonc.2018.06.006 DO - 10.1016/j.critrevonc.2018.06.006 ID - Felice2018 ER - TY - JOUR AU - Kudo, M. PY - 2017 DA - 2017// TI - Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials JO - Oncology. VL - 92 UR - https://doi.org/10.1159/000451016 DO - 10.1159/000451016 ID - Kudo2017 ER - TY - JOUR AU - Popovic, L. S. AU - Matovina-Brko, G. AU - Popovic, M. PY - 2017 DA - 2017// TI - Checkpoint inhibitors in the treatment of urological malignancies JO - ESMO Open. VL - 2 UR - https://doi.org/10.1136/esmoopen-2017-000165 DO - 10.1136/esmoopen-2017-000165 ID - Popovic2017 ER - TY - JOUR AU - Weber, M. M. AU - Fottner, C. PY - 2018 DA - 2018// TI - Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia JO - Oncol Res Treat. VL - 41 UR - https://doi.org/10.1159/000488996 DO - 10.1159/000488996 ID - Weber2018 ER - TY - JOUR AU - Ventriglia, J. AU - Paciolla, I. AU - Pisano, C. AU - Cecere, S. C. AU - Napoli, M. AU - Tambaro, R. PY - 2017 DA - 2017// TI - Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives JO - Cancer Treat Rev. VL - 59 UR - https://doi.org/10.1016/j.ctrv.2017.07.008 DO - 10.1016/j.ctrv.2017.07.008 ID - Ventriglia2017 ER - TY - JOUR AU - Frenel, J. S. AU - Tourneau, C. AU - O'Neil, B. AU - Ott, P. A. AU - Piha-Paul, S. A. AU - Gomez-Roca, C. PY - 2017 DA - 2017// TI - Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial JO - J Clin Oncol. VL - 35 UR - https://doi.org/10.1200/JCO.2017.74.5471 DO - 10.1200/JCO.2017.74.5471 ID - Frenel2017 ER - TY - JOUR AU - Hollebecque, A. n. t. o. i. n. e. AU - Meyer, T. i. m. AU - Moore, K. a. t. h. l. e. e. n. N. AU - Machiels, J. e. a. n. -. P. a. s. c. a. l. H. AU - De Greve, J. a. c. q. u. e. s. AU - López-Picazo, J. o. s. é. M. a. r. í. a. AU - Oaknin, A. n. a. AU - Kerger, J. o. s. e. p. h. N. AU - Boni, V. a. l. e. n. t. i. n. a. AU - Evans, T. R. J. e. f. f. r. y. AU - Kristeleit, R. e. b. e. c. c. a. S. o. p. h. i. e. AU - Rao, S. h. a. n. g. b. a. n. g. AU - Soumaoro, I. b. r. a. h. i. m. a. AU - Cao, Z. A. l. e. x. a. n. d. e. r. AU - Topalian, S. u. z. a. n. n. e. L. o. u. i. s. e. PY - 2017 DA - 2017// TI - An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers JO - Journal of Clinical Oncology VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.5504 DO - 10.1200/JCO.2017.35.15_suppl.5504 ID - Hollebecque2017 ER - TY - JOUR AU - Morris, V. K. AU - Salem, M. E. AU - Nimeiri, H. AU - Iqbal, S. AU - Singh, P. AU - Ciombor, K. PY - 2017 DA - 2017// TI - Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study JO - Lancet Oncol. VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30104-3 DO - 10.1016/S1470-2045(17)30104-3 ID - Morris2017 ER - TY - JOUR AU - Seiwert, T. Y. AU - Burtness, B. AU - Mehra, R. AU - Weiss, J. AU - Berger, R. AU - Eder, J. P. PY - 2016 DA - 2016// TI - Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30066-3 DO - 10.1016/S1470-2045(16)30066-3 ID - Seiwert2016 ER - TY - JOUR AU - Zandberg, D. P. AU - Algazi, A. P. AU - Jimeno, A. AU - Good, J. S. AU - Fayette, J. AU - Bouganim, N. PY - 2019 DA - 2019// TI - Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >/=25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy JO - Eur J Cancer. VL - 107 UR - https://doi.org/10.1016/j.ejca.2018.11.015 DO - 10.1016/j.ejca.2018.11.015 ID - Zandberg2019 ER - TY - JOUR AU - Gardiner, D. AU - Lalezari, J. AU - Lawitz, E. AU - DiMicco, M. AU - Ghalib, R. AU - Reddy, K. R. PY - 2013 DA - 2013// TI - A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection JO - PLoS One. VL - 8 UR - https://doi.org/10.1371/journal.pone.0063818 DO - 10.1371/journal.pone.0063818 ID - Gardiner2013 ER - TY - JOUR AU - Sangro, B. AU - Gomez-Martin, C. AU - Mata, M. AU - Inarrairaegui, M. AU - Garralda, E. AU - Barrera, P. PY - 2013 DA - 2013// TI - A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C JO - J Hepatol. VL - 59 UR - https://doi.org/10.1016/j.jhep.2013.02.022 DO - 10.1016/j.jhep.2013.02.022 ID - Sangro2013 ER - TY - JOUR AU - Duffy, A. G. AU - Ulahannan, S. V. AU - Makorova-Rusher, O. AU - Rahma, O. AU - Wedemeyer, H. AU - Pratt, D. PY - 2017 DA - 2017// TI - Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma JO - J Hepatol. VL - 66 UR - https://doi.org/10.1016/j.jhep.2016.10.029 DO - 10.1016/j.jhep.2016.10.029 ID - Duffy2017 ER - TY - JOUR AU - El-Khoueiry, A. B. AU - Sangro, B. AU - Yau, T. AU - Crocenzi, T. S. AU - Kudo, M. AU - Hsu, C. PY - 2017 DA - 2017// TI - Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial JO - Lancet. VL - 389 UR - https://doi.org/10.1016/S0140-6736(17)31046-2 DO - 10.1016/S0140-6736(17)31046-2 ID - El-Khoueiry2017 ER - TY - JOUR AU - Ma, B. B. Y. AU - Lim, W. T. AU - Goh, B. C. AU - Hui, E. P. AU - Lo, K. W. AU - Pettinger, A. PY - 2018 DA - 2018// TI - Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742) JO - J Clin Oncol. VL - 36 UR - https://doi.org/10.1200/JCO.2017.77.0388 DO - 10.1200/JCO.2017.77.0388 ID - Ma2018 ER - TY - JOUR AU - Hsu, C. AU - Lee, S. H. AU - Ejadi, S. AU - Even, C. AU - Cohen, R. B. AU - Tourneau, C. PY - 2017 DA - 2017// TI - Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study JO - J Clin Oncol. VL - 35 UR - https://doi.org/10.1200/JCO.2017.73.3675 DO - 10.1200/JCO.2017.73.3675 ID - Hsu2017 ER - TY - JOUR AU - Kwong, Y. L. AU - Chan, T. S. Y. AU - Tan, D. AU - Kim, S. J. AU - Poon, L. M. AU - Mow, B. PY - 2017 DA - 2017// TI - PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-12-756841 DO - 10.1182/blood-2016-12-756841 ID - Kwong2017 ER - TY - JOUR AU - Kim, S. J. AU - Hyeon, J. AU - Cho, I. AU - Ko, Y. H. AU - Kim, W. S. PY - 2019 DA - 2019// TI - Comparison of efficacy of pembrolizumab between Epstein-Barr virus-positive and -negative relapsed or refractory non-hodgkin lymphomas JO - Cancer Res Treat. VL - 51 UR - https://doi.org/10.4143/crt.2018.191 DO - 10.4143/crt.2018.191 ID - Kim2019 ER - TY - JOUR AU - Kim, S. T. AU - Cristescu, R. AU - Bass, A. J. AU - Kim, K. M. AU - Odegaard, J. I. AU - Kim, K. PY - 2018 DA - 2018// TI - Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer JO - Nat Med. VL - 24 UR - https://doi.org/10.1038/s41591-018-0101-z DO - 10.1038/s41591-018-0101-z ID - Kim2018 ER - TY - JOUR AU - Mishima, S. AU - Kawazoe, A. AU - Nakamura, Y. AU - Sasaki, A. AU - Kotani, D. AU - Kuboki, Y. PY - 2019 DA - 2019// TI - Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer JO - J Immunother Cancer. VL - 7 UR - https://doi.org/10.1186/s40425-019-0514-3 DO - 10.1186/s40425-019-0514-3 ID - Mishima2019 ER - TY - STD TI - Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with hiv infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019. ID - ref27 ER - TY - JOUR AU - Otter, S. AU - Whitaker, S. AU - Chatterjee, J. AU - Stewart, A. PY - 2019 DA - 2019// TI - The human papillomavirus as a common pathogen in oropharyngeal, anal and cervical cancers JO - Clin Oncol (R Coll Radiol). VL - 31 UR - https://doi.org/10.1016/j.clon.2018.10.004 DO - 10.1016/j.clon.2018.10.004 ID - Otter2019 ER - TY - JOUR AU - Jemal, A. AU - Simard, E. P. AU - Dorell, C. AU - Noone, A. M. AU - Markowitz, L. E. AU - Kohler, B. PY - 2013 DA - 2013// TI - Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels JO - J Natl Cancer Inst. VL - 105 UR - https://doi.org/10.1093/jnci/djs491 DO - 10.1093/jnci/djs491 ID - Jemal2013 ER - TY - STD TI - Symer MM, Yeo HL. Recent advances in the management of anal cancer. F1000Research. 2018;7. ID - ref30 ER - TY - JOUR AU - Solomon, B. AU - Young, R. J. AU - Rischin, D. PY - 2018 DA - 2018// TI - Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments JO - Semin Cancer Biol. VL - 52 UR - https://doi.org/10.1016/j.semcancer.2018.01.008 DO - 10.1016/j.semcancer.2018.01.008 ID - Solomon2018 ER - TY - JOUR AU - Gillison, M. L. AU - Chaturvedi, A. K. AU - Anderson, W. F. AU - Fakhry, C. PY - 2015 DA - 2015// TI - Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma JO - J Clin Oncol. VL - 33 UR - https://doi.org/10.1200/JCO.2015.61.6995 DO - 10.1200/JCO.2015.61.6995 ID - Gillison2015 ER - TY - JOUR AU - Ang, K. K. AU - Harris, J. AU - Wheeler, R. AU - Weber, R. AU - Rosenthal, D. I. AU - Nguyen-Tan, P. F. PY - 2010 DA - 2010// TI - Human papillomavirus and survival of patients with oropharyngeal cancer JO - New England J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa0912217 DO - 10.1056/NEJMoa0912217 ID - Ang2010 ER - TY - JOUR AU - Cleary, C. AU - Leeman, J. E. AU - Higginson, D. S. AU - Katabi, N. AU - Sherman, E. AU - Morris, L. PY - 2016 DA - 2016// TI - Biological features of human papillomavirus-related head and neck cancers contributing to improved response JO - Clin Oncol (R Coll Radiol). VL - 28 UR - https://doi.org/10.1016/j.clon.2016.03.001 DO - 10.1016/j.clon.2016.03.001 ID - Cleary2016 ER - TY - JOUR AU - Fakhry, C. AU - Westra, W. H. AU - Li, S. AU - Cmelak, A. AU - Ridge, J. A. AU - Pinto, H. PY - 2008 DA - 2008// TI - Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial JO - J Natl Cancer Inst. VL - 100 UR - https://doi.org/10.1093/jnci/djn011 DO - 10.1093/jnci/djn011 ID - Fakhry2008 ER - TY - JOUR AU - Lassen, P. AU - Eriksen, J. G. AU - Hamilton-Dutoit, S. AU - Tramm, T. AU - Alsner, J. AU - Overgaard, J. PY - 2009 DA - 2009// TI - Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck JO - J Clin Oncol. VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.2853 DO - 10.1200/JCO.2008.20.2853 ID - Lassen2009 ER - TY - JOUR AU - Ghanizada, M. AU - Jakobsen, K. K. AU - Gronhoj, C. AU - Buchwald, C. PY - 2019 DA - 2019// TI - The effects of checkpoint inhibition on head and neck squamous cell carcinoma: a systematic review JO - Oral Oncol. VL - 90 UR - https://doi.org/10.1016/j.oraloncology.2019.01.018 DO - 10.1016/j.oraloncology.2019.01.018 ID - Ghanizada2019 ER - TY - STD TI - Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018;3. ID - ref38 ER - TY - JOUR AU - Ferris, R. L. AU - Blumenschein, G. AU - Fayette, J. AU - Guigay, J. AU - Colevas, A. D. AU - Licitra, L. PY - 2018 DA - 2018// TI - Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression JO - Oral Oncol. VL - 81 UR - https://doi.org/10.1016/j.oraloncology.2018.04.008 DO - 10.1016/j.oraloncology.2018.04.008 ID - Ferris2018 ER - TY - JOUR AU - Ferris, R. L. AU - Blumenschein, G. AU - Fayette, J. AU - Guigay, J. AU - Colevas, A. D. AU - Licitra, L. PY - 2016 DA - 2016// TI - Nivolumab for recurrent squamous-cell carcinoma of the head and neck JO - N Engl J Med. VL - 375 UR - https://doi.org/10.1056/NEJMoa1602252 DO - 10.1056/NEJMoa1602252 ID - Ferris2016 ER - TY - JOUR AU - Bauml, J. AU - Seiwert, T. Y. AU - Pfister, D. G. AU - Worden, F. AU - Liu, S. V. AU - Gilbert, J. PY - 2017 DA - 2017// TI - Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study JO - J Clin Oncol. VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.1524 DO - 10.1200/JCO.2016.70.1524 ID - Bauml2017 ER - TY - JOUR AU - Cheng, A. L. AU - Kang, Y. K. AU - Chen, Z. AU - Tsao, C. J. AU - Qin, S. AU - Kim, J. S. PY - 2009 DA - 2009// TI - Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial JO - Lancet Oncol. VL - 10 UR - https://doi.org/10.1016/S1470-2045(08)70285-7 DO - 10.1016/S1470-2045(08)70285-7 ID - Cheng2009 ER - TY - JOUR AU - Greten, T. F. AU - Duffy, A. G. AU - Korangy, F. PY - 2013 DA - 2013// TI - Hepatocellular carcinoma from an immunologic perspective JO - Clin Cancer Res. VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-1721 DO - 10.1158/1078-0432.CCR-13-1721 ID - Greten2013 ER - TY - STD TI - Yin H, Qu J, Peng Q, Gan R. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med Microbiol Immunol. 2018. ID - ref44 ER - TY - STD TI - Lam WKJ, Chan JYK. Recent advances in the management of nasopharyngeal carcinoma. F1000Res. 2018;7. ID - ref45 ER - TY - JOUR AU - Jin, Y. AU - Cai, X. Y. AU - Shi, Y. X. AU - Xia, X. Y. AU - Cai, Y. C. AU - Cao, Y. PY - 2012 DA - 2012// TI - Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma JO - J Cancer Res Clin. VL - 138 UR - https://doi.org/10.1007/s00432-012-1219-x DO - 10.1007/s00432-012-1219-x ID - Jin2012 ER - TY - JOUR AU - Goto, Y. AU - Kodaira, T. AU - Fuwa, N. AU - Mizoguchi, N. AU - Nakahara, R. AU - Nomura, M. PY - 2013 DA - 2013// TI - Alternating chemoradiotherapy in patients with nasopharyngeal cancer: prognostic factors and proposal for individualization of therapy JO - J Radiat Res. VL - 54 UR - https://doi.org/10.1093/jrr/rrs071 DO - 10.1093/jrr/rrs071 ID - Goto2013 ER - TY - JOUR AU - Dou, H. Q. AU - Hu, D. Y. AU - Lam, C. AU - Liu, Y. S. AU - Wang, X. W. AU - Zhang, W. D. PY - 2014 DA - 2014// TI - Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Macao JO - Chinese J Cancer Res. VL - 26 ID - Dou2014 ER - TY - JOUR AU - Hong, M. AU - Tang, K. AU - Qian, J. AU - Deng, H. AU - Zeng, M. AU - Zheng, S. PY - 2018 DA - 2018// TI - Immunotherapy for EBV-associated nasopharyngeal carcinoma JO - Crit Rev Oncog. VL - 23 UR - https://doi.org/10.1615/CritRevOncog.2018027528 DO - 10.1615/CritRevOncog.2018027528 ID - Hong2018 ER - TY - STD TI - Shannon-Lowe C, Rickinson AB, Bell AI. Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond B Biol Sci. 2017;372. ID - ref50 ER - TY - BOOK PY - 2012 DA - 2012// TI - A review of human carcinogens. In: Biological agents. Volume 100 B, edn ID - ref51 ER - TY - JOUR AU - Gay, C. L. AU - Bosch, R. J. AU - Ritz, J. AU - Hataye, J. M. AU - Aga, E. AU - Tressler, R. L. PY - 2017 DA - 2017// TI - Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy JO - J Infect Dis. VL - 215 UR - https://doi.org/10.1093/infdis/jix191 DO - 10.1093/infdis/jix191 ID - Gay2017 ER - TY - JOUR AU - Colston, E. AU - Grasela, D. AU - Gardiner, D. AU - Bucy, R. P. AU - Vakkalagadda, B. AU - Korman, A. J. PY - 2018 DA - 2018// TI - An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients JO - PLoS One. VL - 13 UR - https://doi.org/10.1371/journal.pone.0198158 DO - 10.1371/journal.pone.0198158 ID - Colston2018 ER - TY - JOUR AU - Tagaya, Y. AU - Gallo, R. C. PY - 2017 DA - 2017// TI - The exceptional oncogenicity of HTLV-1 JO - Front Microbiol. VL - 8 UR - https://doi.org/10.3389/fmicb.2017.01425 DO - 10.3389/fmicb.2017.01425 ID - Tagaya2017 ER - TY - JOUR AU - Spencer, C. N. AU - Wells, D. K. AU - LaVallee, T. M. PY - 2019 DA - 2019// TI - It is a capital mistake to theorize who to treat with checkpoint inhibitors before one has data JO - Trends in Cancer. VL - 5 UR - https://doi.org/10.1016/j.trecan.2018.12.003 DO - 10.1016/j.trecan.2018.12.003 ID - Spencer2019 ER - TY - JOUR AU - Walboomers, J. M. M. AU - Jacobs, M. V. AU - Manos, M. M. AU - Bosch, F. X. AU - Kummer, J. A. AU - Shah, K. V. PY - 1999 DA - 1999// TI - Human papillomavirus is a necessary cause of invasive cervical cancer worldwide JO - J Pathol. VL - 189 UR - https://doi.org/3.0.CO;2-F DO - 3.0.CO;2-F ID - Walboomers1999 ER - TY - JOUR AU - Arzumanyan, A. AU - Reis, H. M. G. P. V. AU - Feitelson, M. A. PY - 2013 DA - 2013// TI - Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma JO - Nature Reviews Cancer. VL - 13 UR - https://doi.org/10.1038/nrc3449 DO - 10.1038/nrc3449 ID - Arzumanyan2013 ER - TY - JOUR AU - Kobayashi, K. a. z. u. h. i. r. o. AU - Hisamatsu, K. e. n. j. i. AU - Suzui, N. a. t. s. u. k. o. AU - Hara, A. k. i. r. a. AU - Tomita, H. i. r. o. y. u. k. i. AU - Miyazaki, T. a. t. s. u. h. i. k. o. PY - 2018 DA - 2018// TI - A Review of HPV-Related Head and Neck Cancer JO - Journal of Clinical Medicine VL - 7 UR - https://doi.org/10.3390/jcm7090241 DO - 10.3390/jcm7090241 ID - Kobayashi2018 ER - TY - JOUR AU - McFadden, K. AU - Luftig, M. A. PY - 2013 DA - 2013// TI - Interplay between DNA tumor viruses and the host DNA damage response JO - Curr Top Microbiol Immunol. VL - 371 ID - McFadden2013 ER - TY - JOUR AU - Turnell, A. S. AU - Grand, R. J. PY - 2012 DA - 2012// TI - DNA viruses and the cellular DNA-damage response JO - J Gen Virol. VL - 93 UR - https://doi.org/10.1099/vir.0.044412-0 DO - 10.1099/vir.0.044412-0 ID - Turnell2012 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. AU - Havel, J. J. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science. VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Dyck, L. AU - Mills, K. H. G. PY - 2017 DA - 2017// TI - Immune checkpoints and their inhibition in cancer and infectious diseases JO - Eur J Immunol. VL - 47 UR - https://doi.org/10.1002/eji.201646875 DO - 10.1002/eji.201646875 ID - Dyck2017 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer. VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Yang, W. AU - Song, Y. AU - Lu, Y. -. L. AU - Sun, J. -. Z. AU - Wang, H. -. W. PY - 2013 DA - 2013// TI - Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia JO - Immunology. VL - 139 UR - https://doi.org/10.1111/imm.12101 DO - 10.1111/imm.12101 ID - Yang2013 ER - TY - JOUR AU - Heeren, A. M. AU - Punt, S. AU - Bleeker, M. C. G. AU - Gaarenstroom, K. N. AU - Velden, J. AU - Kenter, G. G. PY - 2016 DA - 2016// TI - Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix JO - Modern Pathology. VL - 29 UR - https://doi.org/10.1038/modpathol.2016.64 DO - 10.1038/modpathol.2016.64 ID - Heeren2016 ER - TY - JOUR AU - Yang, W. AU - Lu, Y. P. AU - Yang, Y. Z. AU - Kang, J. R. AU - Jin, Y. D. AU - Wang, H. W. PY - 2017 DA - 2017// TI - Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status JO - J Obstet Gynaecol Res. VL - 43 UR - https://doi.org/10.1111/jog.13411 DO - 10.1111/jog.13411 ID - Yang2017 ER - TY - JOUR AU - Schneider, S. AU - Kadletz, L. AU - Wiebringhaus, R. AU - Kenner, L. AU - Selzer, E. AU - Füreder, T. PY - 2018 DA - 2018// TI - PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome JO - Histopathology. VL - 73 UR - https://doi.org/10.1111/his.13646 DO - 10.1111/his.13646 ID - Schneider2018 ER - TY - STD TI - Qu Y, Wang D, Yang L, Liu HY, Cui W, Che YQ. Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. Mol Clin Oncol. 2018. ID - ref68 ER - TY - JOUR AU - Maruse, Y. AU - Kawano, S. AU - Jinno, T. AU - Matsubara, R. AU - Goto, Y. AU - Kaneko, N. PY - 2018 DA - 2018// TI - Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma JO - Int J Oral Maxillofac Surg VL - 47 UR - https://doi.org/10.1016/j.ijom.2018.01.004 DO - 10.1016/j.ijom.2018.01.004 ID - Maruse2018 ER - TY - JOUR AU - Fang, W. AU - Zhang, J. AU - Hong, S. AU - Zhan, J. AU - Chen, N. AU - Qin, T. PY - 2014 DA - 2014// TI - EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy JO - Oncotarget. VL - 5 ID - Fang2014 ER - TY - JOUR AU - Green, M. R. AU - Rodig, S. AU - Juszczynski, P. AU - Ouyang, J. AU - Sinha, P. AU - O'Donnell, E. PY - 2012 DA - 2012// TI - Constitutive AP-1 activity and EBV infection induce PD-l1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy JO - Clin Cancer Res. VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-1942 DO - 10.1158/1078-0432.CCR-11-1942 ID - Green2012 ER - TY - JOUR AU - Bass, A. J. AU - Thorsson, V. AU - Shmulevich, I. AU - Reynolds, S. M. AU - Miller, M. AU - Bernard, B. PY - 2014 DA - 2014// TI - Comprehensive molecular characterization of gastric adenocarcinoma JO - Nature. VL - 513 UR - https://doi.org/10.1038/nature13480 DO - 10.1038/nature13480 ID - Bass2014 ER - TY - JOUR AU - Lyford-Pike, S. AU - Peng, S. AU - Young, G. D. AU - Taube, J. M. AU - Westra, W. H. AU - Akpeng, B. PY - 2013 DA - 2013// TI - Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma JO - Cancer Res. VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-2384 DO - 10.1158/0008-5472.CAN-12-2384 ID - Lyford-Pike2013 ER -